Alphamab Oncology
HKEX:9966.HK
2.53 (HKD) • At close September 19, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Omzet
| 218.774 | 166.845 | 146.021 | 0 | 4.992 | -0.735 | 1.223 |
| Kosten van de omzet
| 55.237 | 44.207 | 3.028 | 0 | 0 | 0 | 0 |
| Brutowinst
| 163.537 | 122.638 | 142.993 | 0 | 4.992 | -0.735 | 1.223 |
| Brutowinstmarge
| 0.748 | 0.735 | 0.979 | 0 | 1 | 1 | 1 |
| Onderzoek- en ontwikkelingskosten
| 407.524 | 468.238 | 481.361 | 331.241 | 166.654 | 65.608 | 53.221 |
| Algemene en administratieve kosten
| 79.338 | 86.771 | 77.251 | 78.208 | 154.297 | 13.315 | 6.631 |
| Verkoop- en marketingkosten
| 0 | 0.169 | 0.299 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 79.338 | 86.94 | 77.55 | 78.208 | 154.297 | 13.315 | 6.631 |
| Overige kosten
| -0.095 | 0.473 | 5.36 | 0 | -4.992 | -27.372 | 0.04 |
| Bedrijfskosten
| 469.087 | 468.02 | 570.035 | 480.6 | 315.959 | 96.023 | 65.063 |
| Bedrijfsresultaat
| -323.325 | -432.371 | -415.619 | -409.449 | -829.134 | -131.708 | -64.818 |
| Bedrijfsresultaat ratio
| -1.478 | -2.591 | -2.846 | 0 | -166.093 | 179.195 | -52.999 |
| Totaal overige inkomsten en kosten netto
| 112.732 | 106.649 | 3.202 | -18.317 | -3.606 | -70.925 | -0.008 |
| Inkomen voor belasting
| -210.593 | -325.722 | -412.417 | -427.766 | -832.74 | -202.633 | -64.826 |
| Inkomen voor belasting ratio
| -0.963 | -1.952 | -2.824 | 0 | -166.815 | 275.691 | -53.006 |
| Belastingkosten
| 124.911 | 40.314 | 28.284 | 0 | 3.606 | 16.628 | -31.765 |
| Nettowinst
| -210.593 | -325.722 | -412.417 | -427.766 | -836.346 | -149.843 | -33.061 |
| Nettowinstmarge
| -0.963 | -1.952 | -2.824 | 0 | -167.537 | 203.868 | -27.033 |
| WPA (Winst Per Aandeel)
| -0.22 | -0.35 | -0.44 | -0.46 | -1.56 | -0.17 | -0.037 |
| Verwaterde WPA
| -0.22 | -0.35 | -0.44 | -0.46 | -1.56 | -0.17 | -0.037 |
| EBITDA
| -129.296 | -391.829 | -387.098 | -390.469 | -817.361 | -125.146 | -64.304 |
| EBITDA ratio
| -0.591 | -2.348 | -2.651 | 0 | -163.734 | 170.267 | -52.579 |